SCHEDULE 13G/A: Intracoastal Capital and Affiliates Disclose 8.8% Stake in Mustang Bio, Inc.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a collective beneficial ownership of 8.8% in Mustang Bio, Inc., primarily through common stock and exercisable warrants.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Mustang Bio, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially owned 236,452 shares of Mustang Bio, Inc. common stock.
• This ownership represents approximately 8.8% of the company's common stock.
• The 236,452 shares consist of 184,000 shares directly held by Intracoastal Capital LLC and 52,452 shares issuable upon the exercise of 'Intracoastal Warrant 1'.
• The calculation of the 8.8% ownership is based on 1,295,338 shares of common stock outstanding as of January 31, 2025, as reported by Mustang Bio, Inc., plus the 52,452 shares from 'Intracoastal Warrant 1'.
• The filing explicitly excludes 664,452 shares from 'Intracoastal Warrant 2' and 664,452 shares from 'Intracoastal Warrant 3' due to blocker provisions.
• These blocker provisions prevent the exercise of 'Intracoastal Warrant 2' and 'Intracoastal Warrant 3' if such exercise would result in beneficial ownership exceeding 4.99% of the common stock by the holder and their affiliates.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 1,565,356 shares of common stock.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Mustang Bio, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a positive or negative sentiment.

Future Outlook

The document indicates that additional shares (664,452 from Intracoastal Warrant 2 and 664,452 from Intracoastal Warrant 3) are issuable upon exercise of warrants at the closing of a transaction contemplated by a Sale and Purchase Agreement (SPA), subject to 4.99% beneficial ownership blocker provisions.

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an institutional investor group in a publicly traded company, common across various industries, including biotechnology (which Mustang Bio, Inc. operates in). It does not provide specific industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor group may be viewed positively, indicating confidence in the company, though the filing explicitly states the stake is not for control purposes.
• Company Management: Awareness of a significant shareholder group and their ownership structure, including warrant terms and blocker provisions.

Next Steps

• Potential future exercise of 'Intracoastal Warrant 2' and 'Intracoastal Warrant 3' upon the closing of the transaction contemplated by the SPA, subject to the 4.99% blocker provisions.

Key Dates

Keywords

Mustang Bio Inc., Intracoastal Capital LLC, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Equity Stake, SEC Filing